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Summary
Expression of tissue-specific homing molecules di-
rects antigen-experienced T cells to particular periph-
eral tissues. In studies using soluble antigens that
focused on skin and gut, antigen-presenting cells
(APCs) within regional lymphoid tissues were pro-
posed to be responsible for imprinting homing phe-
notypes. Whether this occurs in other sites and after
physiologic antigen processing and presentation is
unknown. We define in vivo imprinting of distinct
homing phenotypes on monospecific T cells respond-
ing to antigens expressed by tumors in intracerebral,
subcutaneous, and intraperitoneal sites with efficient
brain-tropism of CD8 T cells crossprimed in the cervi-
cal lymph nodes (LNs). Multiple imprinting programs
could occur simultaneously in the same LN when tu-
mors were present in more than one site. Thus, the
identity of the LN is not paramount in determining the
homing phenotype; this critical functional parameter
is dictated upstream at the site of antigen capture by
crosspresenting APCs.
Introduction
The tissue-tropism of activated T lymphocytes is gov-
erned by sequential interactions between a complex ar-*Correspondence: paul.walker@hcuge.ch
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M5G 2C1, Canada.ray of adhesion molecules (i.e., selectins, integrins, immu-
noglobulin superfamily members, and their counter-
receptors) variably expressed by T cells and endothelial
cells (Butcher and Picker, 1996; von Andrian and Mackay,
2000). Moreover, enhanced adhesion to the vascular
endothelium and subsequent transmigration into tis-
sues is facilitated by triggering of chemokine receptors
on T cells (Butcher and Picker, 1996; von Andrian and
Mackay, 2000; Kunkel and Butcher, 2002). This has led
to the concept that tissue-specific combinations of ad-
hesion molecules and chemokines provide an area
code allowing the selective recruitment of T cell pop-
ulations to different regions of the body (Kunkel and
Butcher, 2002).
This concept has been explored principally for two of
the major epithelial surfaces of the body, the skin and
the gastrointestinal tract, that are infiltrated by T cells
characterized by distinct adhesive properties (Fuhl-
brigge et al., 1997; Butcher et al., 1999). In vivo obser-
vations of CD4 T cell responses to soluble ovalbumin
indicated that this skin/gut dichotomy in T cell traffick-
ing reflects a differential modulation of adhesive mole-
cules and chemokine responsiveness during T cell
priming in regional lymphoid organs (Campbell and
Butcher, 2002). Specifically, there was a preferential
upregulation of P-selectin ligands (P-Lig) on T cells
primed in skin-draining lymph nodes (LNs) and of α4β7
integrin on T cells primed in intestinal LNs. For CD8 T
cell responses, recent in vitro priming experiments have
shown the influence of different subsets of dendritic
cells (DCs) on the determination of skin- and gut-tropic
phenotypes (Stagg et al., 2002; Mora et al., 2003;
Johansson-Lindbom et al., 2003; Dudda et al., 2004).
Indeed, peptide-pulsed Langerhans cells induced ex-
pression of the putative skin-homing receptor E-selectin
ligand (E-lig) on CD8 T cells primed in vitro, whereas
peptide-pulsed DCs isolated from Peyer’s patches or
mesenteric LNs (mLNs), but not from other lymphoid
tissues, preferentially induced α4β7 integrin.
Concerning in vivo studies, skin- and gut-tropic phe-
notypes were induced on CD8 cells in vivo using pep-
tide-pulsed bone marrow (BM)-derived DCs injected
using different routes (Dudda et al., 2004). A key out-
standing issue for phenotypic imprinting is how this oc-
curs after in vivo antigen delivery. In view of the multiple
subsets of DCs detectable in murine LNs (Ardavin,
2003), it is possible that different imprinting programs
are induced by distinct DC populations. Specialized DC
subsets participate in the presentation of soluble or
cell-associated antigens to CD8 T cells (a process
known as crosspresentation) (Pooley et al., 2001; den
Haan et al., 2000). Moreover, during an immune re-
sponse, antigen-presenting cells (APCs) immigrate into
LNs and display antigens captured in peripheral tissues
(Itano et al., 2003; Garg et al., 2003). Thus, regional
priming of CD8 T cell responses in vivo may rely either
on specialized LN-resident DCs or on APCs migrating
from the tissues. Assessing whether and how the in
vivo tissue distribution of antigens recognized by CD8
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is thus an important issue to address.
In this study, we assessed whether different homing
phenotypes are imposed on potentially beneficial CD8
T cells responding to subcutaneous (s.c.), intraperito-
neal (i.p.), or intracerebral (i.c.) tumors. We investigated
responses to the latter category of tumor in particular
detail because previous studies of brain tropism have
concentrated on the effector stage (Engelhardt et al.,
1995; Engelhardt et al., 1998b; Alon, 2001; Roffe et al.,
2003) without addressing how and where such tropism
is induced during priming. We monitored phenotypic
changes of tumor-specific T cells from their priming
phase in lymphoid organs to their effector phase in tu-
mor-bearing tissues, and we show that immune re-
sponses to CNS-derived antigens are associated with
the instruction of a novel homing phenotype different
from that initiated against s.c. or i.p. tumors. This new
imprinting program in CNS-draining LNs resulted in a
modest upregulation of P-Lig and E-Lig and a major
upregulation of α4 and β1 integrins (but not β7 integrin),
conferring preferential CNS-tropism. Moreover, we pro-
vide evidence that T cell homing phenotypes are not
predetermined by the LNs in which priming occurs but
are defined at the site of antigen capture by cross-
presenting APCs.
Results
Regional Priming of Antitumor T Cells
We initially defined whether different lymphoid organs
participate in the activation of tumor-specific CD8 T
cells following the implantation of an experimental tu-
mor at different sites. We combined the implantation of
FMC57-GP tumors, expressing the lymphocytic chorio-
C
meningitis virus glycoprotein (GP) with the adoptive S
transfer of 5-[and-6-]-carboxyfluorescein diacetate, suc- M
cinimidyl ester (CFSE)-labeled monospecific naive CD8 c
T cells from P14 TCR transgenic mice recognizing the s
(H-2Db-restricted GP33–41 epitope. To identify the sites
iof T cell priming induced by i.c., s.c., or i.p. tumors, we
cdetermined which lymphoid tissues displayed prolifera-
C
tion of CFSE-labeled cells 4 days after MC57-GP im- (
plantation. In animals implanted i.c., there was prolifer- s
ation of P14 CD8 T cells in deep and superficial cervical F
(LNs (cLNs) as well as in lumbar LNs, while no signifi-
(cant proliferation was observed in spleen or any of the
sfollowing LNs tested: axillary, brachial, inguinal, and
D
mesenteric (Figure 1A and Figure S1 available with this a
article online). Proliferation in mice implanted s.c. in the
flank was restricted to the ipsilateral inguinal LN (iLN),
whereas animals implanted i.p. exhibited divisions in n
tcLNs, iLNs, and mLNs as well as in most of the lym-
phoid tissues analyzed (Figure 1A and data not shown). C
TThere was no significant proliferation of P14 CD8 T cells
in mice not challenged with tumor (Figure S2). This re- b
cgional activation of P14 CD8 T cells showed that dif-
ferent sets of LNs are alerted by tumors growing at dif- i
ferent locations and characterizes the site of priming of
CD8 T cells specific for a defined antigen expressed by C
Ban i.c. tumor.
CD8 T cells in cLNs reproducibly showed 4–5 division t
(cycles 3 days after i.c. tumor implantation. By day 4,
more than 7 divisions had occurred and significantigure 1. Site of Priming and Kinetics of Activation of GP-Specific
D8 T Cells following MC57-GP Tumor Implantation at Different
ites
ice infused intravenously (i.v.) with CFSE-labeled naive P14 CD8 T
ells were implanted with MC57-GP tumor cells intracerebrally (i.c.),
ubcutaneously in the flank (s.c./flank), or intraperitoneally (i.p).
A) Four days after tumor implantation, the site of CD8 T cell prim-
ng was determined by assessing the proliferation of CFSE-labeled
ells in LNs by flow cytometry. All histograms are gated on
D8+Vα2+ cells.
B) Divisions of CFSE+ P14 CD8 T cells from cLNs taken from mice
acrificed 1, 2, 3, or 4 days after i.c. implantation of MC57-GP cells.
low cytometric analysis of CD8+Vα2+ cells.
C) The intensity of CFSE labeling was measured by flow cytometry
histograms) on brain infiltrating leukocytes (BILs) of mice de-
cribed in B after gating on CD8+Vα2+ cells (gate a in dot plots).
ata are representative of three (A) or four (B and C) individually
nalyzed mice.umbers of GP-specific CD8 T cells were clearly de-
ectable in brain infiltrating leukocytes (BILs) as a
D8+Vα2+CFSE+(low) population (Figures 1B and 1C).
here were no significant CD8+Vα2+CFSE+ cells in BILs
efore day 4 (%5 cells). Therefore, GP-specific CD8 T
ells are rapidly activated in cLNs and quickly migrate
nto the brain in order to perform their effector function.
rosspriming of Antitumor T Cells in Draining LNs
ecause the identity of the priming cell is considered
o dictate the differentiation program of naive T cells
Mora et al., 2003; Johansson-Lindbom et al., 2003;
Dudda et al., 2004), it was critical to define the priming
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177mechanism in our model. Indeed, priming of tumor-
specific CTLs can occur either by direct antigen pre-
sentation by tumor cells or indirectly by crosspresent-
ing APCs (Ochsenbein et al., 2001; Spiotto et al., 2002;
Yu et al., 2003). We previously showed in another model
that APCs crosspresenting tumor antigens are neces-
sary for the activation and intratumoral retention of tu-
mor-specific CTLs following i.c. tumor growth (Calzas-
cia et al., 2003). Whether H-2Db/GP33–41-specific immune
responses in the MC57-GP tumor model also rely on
indirect presentation of tumor antigens is unknown. We
therefore assessed whether GP-specific CD8 T cells
could be primed in mice lacking the MHC class I ele-
ments presenting the immunodominant GP33–41 epitope.
CFSE-labeled P14 CD8 T cells infused into H-2KbDb
knock-out (KO) mice did not proliferate following i.c. im-
plantation of MC57-GP tumors (Figure 2A). However,
the proliferative potential of CFSE+ cells isolated from
cLNs of these KO mice was validated in vitro after stim-
ulation with GP33–41 peptide-pulsed irradiated H-2Db+
spleen cells (Figure 2B). These results indicate that
crosspresenting APCs are necessary for priming GP-
specific CD8 T cells in response to i.c. implanted
MC57-GP tumors, a finding that was confirmed using
β2-microglobulin KO mice (data not shown). We could
not use H-2Kb/Db KO mice to demonstrate crossprim-
ing after s.c. tumor implantation, since adoptively
transferred CFSE-labeled P14 CD8 T cells were elimi-
nated from the recipient mice under these (s.c.) condi-
tions, presumably due to residual CTL and/or NK reac-
tivity in these mice (Vugmeyster et al., 1998). Instead,
we used BM chimeric mice, reconstituted with either
(C57BL/6 x DBA/2)F1 (B6D2) BM (H-2b/d), or DBA/2 BM
(H-2d) to show that P14 CD8 T cell proliferation after s.c.
MC57-GP implantation also required crosspresentation of
tumor-derived GP antigen on BM-derived H-2b express-
ing APCs (Figure 2C).
Adhesion Molecule Expression by T Cells
in Different LNs
It was recently reported that CD4 T cells activated inFigure 2. Priming of GP-Specific CD8 T Cells
Requires Crosspresentation of Tumor Anti-
gens by Endogenous APCs
Priming of CFSE-labeled naive P14 CD8 T
cells was assessed by flow cytometric analy-
sis of CD8+Vα2+ cells.
(A) Wt or H-2KbDb KO mice infused i.v. with
CFSE-labeled naive P14 CD8 T cells were
implanted i.c. with MC57-GP tumors and an-
alyzed 4 days later for divisions of CFSE-
labeled cells from cLNs.
(B) Day 4 cLNs from H-2KbDb KO mice de-
scribed in (A) were stimulated in vitro with
irradiated H-2b+ splenocytes pulsed with the
GP33–41 peptide (bottom) or with an irrelevant
H-2Kb binding peptide derived from oval-
bumin (SIINFEKL, OVA257–264: top). The pro-
liferative capacity of CFSE-labeled cells was
assessed by flow cytometry 3 days later.
(C) Lethally irradiated B6D2 mice were re-
constituted with either B6D2 BM cells (top) or DBA/2 BM cells (bottom), infused i.v. with CFSE-labeled naive P14 CD8 T cells, then implanted
s.c. with MC57-GP tumors. The proliferative capacity of CFSE-labeled cells from iLN was assessed by flow cytometry 4 days later.
A representative result of three (A and B) or four (C) experiments on individual mice is shown.cutaneous LNs (iLN and axillary LNs) and mLNs ex-press different adhesion molecules during priming
using soluble antigen (Campbell and Butcher, 2002). To
determine whether similar differences also apply to tu-
mor-specific CD8 T cells primed in different LNs, we
assessed the expression of integrins (α4, β1, β7, α4β7,
and αEβ7) and selectin ligands (P-Lig and E-Lig) on P14
CD8 T cells activated in cLNs, iLNs, and mLNs. Analy-
ses of LNs from adoptively transferred recipients pre-
viously implanted with MC57-GP tumors i.c., s.c., or i.p.
showed that three distinct populations of dividing cells
could be defined using this selection of markers (Figure
3). Proliferation in CNS-draining LNs (superficial and
deep cLNs, and lumbar LNs) was associated with a
rapid (occurring within the first few divisions) upregula-
tion of α4 and β1 integrin, a rapid downregulation of
αEβ7 but no major alteration of the expression of β7 and
α4β7 integrin (Figure 3 and data not shown).
Because α4 integrin is expressed as α4β1 or α4β7 het-
erodimer at the cell surface (Pribila et al., 2004), these
data are consistent with preferential upregulation of the
α4β1 integrin heterodimer by CD8 T cells activated in
cLNs rather than α4β7. Cells dividing in mLNs displayed
a rapid upregulation of α4, β1, and α4β7 integrins, whereas
the downregulation of αEβ7 followed a unique and
heterogeneous pattern (Figure 3). Tumor-specific CD8
T cells activated in skin-draining iLNs were charac-
terized by a pattern of αEβ7 downregulation that mir-
rored that observed in cLNs, some upregulation of β1
integrin, but in contrast, no obvious upregulation of α4,
β7, or α4β7 integrins was seen (Figure 3). The upregula-
tion of β1 integrins observed in all LNs is consistent
with its previously reported upregulation during T cell
activation (Shimizu et al., 1990). Because the β1 subunit
can pair with at least six different α-subunits on T cells
(Pribila et al., 2004), additional heterodimers are likely
to be upregulated besides the previously discussed
α4β1 integrin in cLNs and α4β7 integrin in mLNs.
Expression of P-Lig and E-Lig on P14 CD8 T cells
showed three distinct patterns depending upon the site
of tumor implantation: a major upregulation in iLNs af-
ter s.c. implantation, an increase after six or seven divi-
sions after i.c. implantation and no increase after i.p.
implantation (Figure 3). The expression pattern of P-Lig
Immunity
178Figure 3. Tumor-Specific T Cells Acquire Dif-
ferent Patterns of Adhesion Molecule Ex-
pression after Priming in Different LNs
Mice infused i.v. with CFSE-labeled naive
P14 CD8 T cells were implanted with MC57-
GP tumor cells i.c., s.c., or i.p. and 4 days
later, the expression of adhesion molecules
was analyzed by flow cytometry on dividing
cells in cLNs, iLNs, or mLNs (for i.c., s.c., and
i.p. implanted mice, respectively). The level
of expression of each indicated marker was
calculated as the geometrical mean fluores-
cence intensity (GMFI ± SEM) and is pre-
sented in function of the division number (as
determined by CFSE content).
(A) Integrin expression assessed by binding
of rat or hamster primary antibodies, re-
vealed with PE-conjugated goat anti-rat or
anti-hamster. Gating was on CD8-CyChrome
binding cells.
(B) Binding of P- and E-selectin-human Fc
fusion proteins (P-Lig and E-Lig), revealed
with a PE-conjugated goat anti-human Fc.
Gating was on CD8-CyChrome binding cells.
Dot plots are representative of three to five
(A), five ([B], cLN), or six ([B], mLN and iLN)
independent experiments, which are pooled
for the GMFI plots with error bars (SEM)
shown except for β1 cLN (Division 7) for
which calculations were based on results
from 2 experiments.on cLN-derived cells was complex in that the average C
sincrease reflected high P-Lig expression on a sub-
population of cells. However, even these P-Lighigh cells e
idividing in the cLN were clearly distinguishable from
P-Lighigh cells from the iLN because in the latter popula- e
Ttion, there was no α4 integrin upregulation. Thus, three
different adhesion patterns characterize GP-specific p
CD8 T cells proliferating in cLNs, iLNs, and mLNs, indi-
cating that besides skin- and gut-tropic-like pheno- C
Itypes, additional imprinting programs exist.
For most of the integrin chains analyzed, the particu- t
ilar expression profiles acquired in the LNs were similar
to those on P14 CD8 T cells isolated from the tumor s
mimplantation sites (Figure S3). However, the different
analysis of activated integrin expression on these cFSE-negative (but tetramer-positive) cells from the tis-
ues does not allow a direct comparison of absolute
xpression levels of the integrin heterodimers induced
n the LNs. Nevertheless, one striking difference was
xpression of αEβ7 by a substantial fraction of P14 CD8
cells present in BILs (rapidly downregulated during
riming in all LNs: Figure 3).
NS-Tropism of cLN-Primed CD8 T Cells
n view of the paucity of information regarding the pheno-
ype of CD8 T cells that enter the brain, we performed
n vivo homing experiments to determine whether tumor-
pecific CD8 T cells primed in cLNs traffic to the brain
ore efficiently than CD8 T cells activated in iLNs. Be-
ause primed and fully differentiated tumor-specific T
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179cells are a minority of the LN T cells isolated at a given
time point, we allowed day-4 cLN or iLN cells isolated
from i.c.- or s.c.-implanted mice to continue their differ-
entiation in vitro, thus augmenting the proportion of ac-
tivated T cells while maintaining differential integrin ex-
pression. This was measured as a 3.6- to 7.6-fold (n =
4) higher expression of α4-integrin by cLN-derived cells
compared to iLN-derived cells (with similar expression
of α4β7 integrin by the two populations; Figure 4A), con-
sistent with preferential α4β1 expression by cLN-derived
CD8 T cells. To compare the relative CNS-tropism of
cLN- and iLN-derived activated CD8 T cells, differenti-
ally labeled CD8+ populations purified after in vitro cul-
ture were infused intravenously (i.v.) into mice bearing
i.c. MC57-GP tumors (infiltration into normal nonin-
flamed brain was minimal; data not shown). In prelimi-
nary experiments, we observed a 2.5-fold preferential
entry of cLN-primed T cells to the brain, compared with
iLN-primed T cells (data not shown). We subsequently
refined the experiment by coinjecting antibodies blocking
either α4 integrin (highly expressed on cLN-primed cells)
or CD11b (as an integrin with no significant expression
by T cells in our model). The relative proportion of cLN-
derived versus iLN-derived cells among activated
CD8+CD62L− T cells was assessed 24 hr later in several
compartments. In the presence of CD11b antibodies,
cLN-derived activated CD8 T cells homed 2.8 times
better to the brain than iLN-derived CD8 T cells (Figure
4B). Interestingly, blocking of α4 reduced entry of both
populations into the brain, but inhibition was greater for
cLN-derived CD8 T cells. Overall, these findings indi-
cate that the phenotype acquired by CD8 T cells in
cLNs provides a better migration into the brain than
that acquired in iLNs, with α4 expression contributing
to brain entry, even if this single integrin does not totally
account for the brain tropism of cLN-primed CD8 T
cells.
Multiple Homing Phenotypes in the Same LN
We reasoned that if APCs constitutively present in each
LN were responsible for the different imprinting pro-
grams we observed, then tumor-specific CD8 T cells
proliferating in cLNs or iLNs after i.p. tumor implanta-
tion should acquire a pattern of adhesion molecule ex-
pression similar to that acquired after tumor growth i.c.
or s.c., respectively. However, i.p. tumors resulted in the
preferential induction of a gut-tropic phenotype (i.e.,
upregulation of α4β7, with no expression of P-Lig) not
only in mLNs (Figure 3) but also on GP-specific CD8 T
cells proliferating in iLNs and in cLNs (Figures 5A and
5B). This suggested that the site of tumor implantation
rather than the identity of a given LN is the main factor
responsible for the final homing phenotype acquired by
tumor-specific CD8 T cells. This concept was substan-
tiated by experiments in which s.c. implantation of
MC57-GP in the proximity of the cLNs (i.e., in the neck;
Figures 5B and S2) imprinted a similar phenotype on
P14 CD8 T cells dividing in cLNs as that induced in iLNs
after s.c. implantation in the flank (Figure 5A).
In order to further explore the contributions of the LN
and the site of tumor implantation in imposing a given
homing phenotype, we studied two antigenically dis-
tinct immune responses occurring simultaneously inFigure 4. GP-Specific CD8 T Cells Primed in cLNs Migrate Better
into the Brain Than CD8 T Cells Primed in iLNs
(A) cLNs and iLNs from mice infused i.v. with unlabeled P14 CD8 T
cells and subsequently implanted with MC57-GP tumors i.c. or s.c.,
respectively, were harvested 4 days after tumor implantation and
cultured for 3 days. The relative expression of α4 and α4β7 integrins
on activated (CD62L−) CD8+ cells was then assessed by flow cyto-
metry on the two populations. Integrin-specific antibody staining is
shown in gray-filled curves with isotype control antibodies in black
open curves.
(B) After culture, CD8 T cells were purified from each population,
labeled with two different concentrations of CFSE (i.e., cLN =
CFSEhigh and iLN = CFSElow) mixed together in equal numbers and
then infused i.v. into recipient mice implanted i.c. with MC57-GP
tumors 6 days previously. A control antibody (CD11b, M1/70) or an
anti α4 integrin antibody (CD49d, PS/2) was injected at the same
time to assess the participation of α4 integrin. The migration index
(i.e., the ratio of CFSEhigh to CFSElow cells in recipient blood or
tissues divided by the input ratio) was measured 24 hr later in recip-
ients’ PBMCs, brain, lung, liver, and spleen. Mean ± SEM of all
experiments is shown (n = 6 for blood, brain, and spleen; n = 3 for
lung and liver). Calculations are based on flow cytometric analysis
of all cells (gated on the CD62L−CD8+CFSE+ adoptively transferred
cells) recovered from entire perfused organs for brain, lung, and
liver, from 6 × 106 cells analyzed from spleen and from 0.5ml blood.
The mean numbers (minimum–maximum) of CD62L−CD8+CFSE+
cells analyzed for each tissue were: PBMCs 436 (167–975), brain
628 (261–1588), lung 260 (131–458), liver 1077 (537–1598), and
spleen 650 (370–809). Statistically significant differences are
marked (t test, *p < 0.05 and **p < 0.01).the same LN after tumor implantation in two different
sites. Ovalbumin (OVA)-specific OT-I CD8 T cells divid-
ing in iLN after s.c. implantation of E.G7-OVA cells
strongly upregulated P-Lig expression, whereas GP-
specific P14 CD8 T cells simultaneously dividing in the
same iLN after i.p. implantation of MC57-GP cells
strongly upregulated α integrin expression (Figure 6).4
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Figure 5. T Cell Homing Phenotypes Are Dictated by the Site of o
Tumor Implantation
r
Mice infused i.v. with CFSE-labeled naive P14 CD8 T cells were
simplanted with MC57-GP tumor cells, and 4 days later, expression
pof selected adhesion molecules was analyzed by flow cytometry
aon dividing cells in the LNs. The level of expression of the indicated
markers (GMFI ± SEM) is displayed in function of the division m
number (as determined by CFSE content). Gating was on CD8- (
CyChrome binding cells. v
(A) Mice were implanted either s.c. in the flank, or i.p., and P14 p
CD8 T cells dividing in the iLN were analyzed for expression of the
oindicated adhesion molecules.
g(B) Mice were implanted either i.c., s.c. in the neck, or i.p. and P14
CD8 T cells dividing in the cLN were analyzed for expression of the
indicated adhesion molecules. t
Means ± SEM of GMFI for each adhesion molecule in function of s
division number are shown ([A]: iLNs/s.c. flank α4 and α4β7 n = 3, C
P-Lig n = 4; iLNs/i.p. α4, α4β7, and P-Lig n = 3. [B]: cLNs/i.c. n = 5; t
cLNs/s.c. neck and cLNs/i.p. n = 6. Mice for iLNs/s.c. flank α4 and Pα4β7 in [A] were the same as in Figure 3, reshown here to facilitate
acomparison).
s
rmune-privileged site in which there are no anatomicallywhere antigenic threats were initially encountered is
Figure 6. Two Independent Imprinting Pro-
grams Can Occur Simultaneously in the
Same LN
Mice coinfused i.v. with CFSE-labeled naive
CD8 T cells from P14 and OT-I TCR Tg mice
were implanted simultaneously i.p. with
MC57-GP cells and s.c. in the flank with
E.G7-OVA cells. Four days later, expression
of the indicated adhesion molecules was an-
alyzed by flow cytometry on dividing (CFSE+)
cells of each specificity (discriminated by
TCR Vβ5 expression of OT-1 T cells) in the
same iLN, shown as a dotplot gated on
Vβ5+CFSE+ (principally OT-1) or Vβ5−CFSE+
(principally P14) populations, and with ex-
pression level calculated as GMFI (±SEM) in
function of division number. Only CFSE+
cells clearly discernable from endogenous
cells (up to 6 divisions) are shown. The data
are calculated from six independent experi-
ments.Discussion L
p
The mechanism by which effector and memory T cells a
can efficiently and preferentially protect those tissues fresumed to be through selection or instruction of
oming phenotypes during priming in regional lym-
hoid tissues. This was suggested by the reciprocal
attern of integrin expression and chemokine respon-
iveness acquired by CD4 T cells activated in either
utaneous or intestinal LNs after the i.p. injection of
oluble antigen and adjuvant (Campbell and Butcher,
002). Recently, in vitro activation of T cells with pep-
ide or anti-CD3 antibody and DCs purified from intesti-
al lymphoid organs was shown to result in a preferen-
ial gut-tropic phenotype (Stagg et al., 2002; Mora et
l., 2003; Johansson-Lindbom et al., 2003), suggesting
hat imprinting of multiple homing phenotypes may be
ue to distinct subsets of DCs in different LNs. How-
ver, it is unknown whether multiple homing pheno-
ypes can be imprinted in vivo on CD8 T cells activated
n different lymphoid tissues after physiological antigen
ptake, an issue that is important for the understanding
f regional immunity. Indeed, CD8 T cell responses are
ften directed against antigens transported from pe-
ipheral tissues to lymphoid organs by specialized sub-
ets of crosspresenting APCs that are different to those
resenting soluble antigens to CD4 T cells (Pooley et
l., 2001; den Haan et al., 2000) or to those used experi-
entally to stimulate CD8 cells after peptide pulsing
Dudda et al., 2004). Moreover, although several obser-
ations indicated the existence of T cells with homing
henotypes different from those induced in cutaneous
r intestinal sites, evidence for the in vivo mechanisms
enerating such alternative phenotypes is still lacking.
In this study, we used an adoptive transfer approach
o dissect the multiple phases during which the expres-
ion pattern of adhesion receptors of tumor-specific
D8 T cells are defined in lymphoid organs following
he s.c., i.p., and i.c. implantation of a model tumor.
riming occurred in a single directly draining local LN
fter s.c. implantation, systemically in many LNs and
pleen after i.p. implantation, and in a limited array of
egional LNs (superficial and deep cLNs and lumbar
Ns) after i.c. implantation (Figure 1). This latter result
rovides the first direct demonstration that both cLNs
nd lumbar LNs support priming of CD8 T cells specific
or antigens expressed by tumors in the brain, an im-
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181defined lymphatic vessels (Walker et al., 2003). This
proof for the specific immunological interactions occur-
ring in these brain draining LNs extends previous find-
ings in which cLNs were shown to be critical for
humoral responses to CNS-injected antigens, for enceph-
alitogenic responses, and for interferon-α-enhanced an-
titumor responses (Weller et al., 1996; Okada et al.,
2004).
Analysis of the adhesion molecules expressed by tu-
mor-specific T cells in vivo allowed us to confirm
whether the previously defined canonical skin- and gut-
homing phenotypes (Fuhlbrigge et al., 1997; Butcher et
al., 1999) were also induced after physiologic antigen
capture and processing. This was the case for the high
levels of α4β7 integrin expressed by CD8 T cells primed
in mLNs following i.p. tumor implantation (i.e., gut-
tropic phenotype) and the high expression of selectin
ligands by CD8 T cells primed in iLNs following s.c.
tumor implantation (i.e., skin-tropic phenotype). How-
ever, our data also reveal previously unreported com-
plexity in adhesion molecule expression patterns in-
duced on monoclonal T cells responding to an identical
tumor implanted in different sites, shown by the dif-
ferential modulation of selectin ligands (P-Lig, E-Lig)
and integrins (α4, β1, β7, α4β7, and αEβ7) on T cells divid-
ing in cLNs, iLNs, and mLNs (Figure 3).
The distinct pattern of adhesion molecule expression
that we observed on the tumor-reactive CD8 T cells di-
viding in CNS-draining LNs in response to i.c. tumors
(principally high α4 and β1 expression and low α4β7 ex-
pression) merited particular attention because this is
the first description of the acquisition of this phenotype
upon priming of naive T cells in vivo. Our data is consis-
tent with previously reported roles of α4β1 in facilitating
CNS entry by encephalitogenic or virus-specific T cells
after interacting with VCAM-1 on cerebral vascular en-
dothelium (Vajkoczy et al., 2001; Alon, 2001; Engelhardt
et al., 1995; Engelhardt et al., 1998b; Irani and Griffin,
1996; Engelhardt et al., 1998a; Carrithers et al., 2000).
However, despite this focus on α4β1 integrin, the ob-
served preferential brain tropism of cLN primed CD8 T
cells is most likely a result of the orchestrated coopera-
tion of multiple receptors. These may include P-Lig and
E-Lig that were modestly but consistently upregulated
on a proportion of P14 CD8 T cells primed in cLNs (Fig-
ure 3). Therefore, more comprehensive understanding
of regional tumor immunity will require the analysis of
multiple adhesion factors (for both CD4 and CD8 T
cells) as well as an assessment of chemokine receptor
expression.
Previous studies investigating how tissue tropism is
imposed on T cells have highlighted APCs and micro-
environment as key factors involved in this important
biological function, but some issues were not ad-
dressed. These include the contributions of the lym-
phoid tissue microenvironment versus the microenvi-
ronment at the site of antigen challenge and the
autonomy of APCs to prime and imprint a given homing
phenotype on T cells in any LN. In our study, we show
that it is the site of tumor implantation and not the iden-
tity of the LN that is paramount in determining the
pattern of phenotypic imprinting on tumor-specific CD8
T cells. Our data are in contrast to those showing dis-
tinct homing phenotypes induced on CD4 T cells in in-testinal or cutaneous LNs after i.p. injection of OVA
(Campbell and Butcher, 2002); this is probably related
to the nature of the antigen used. Vaccination using sol-
uble proteins with adjuvants represents one extreme
immune stimulus, while T cell stimulation by tumor-
expressed antigens may be very different and can
spontaneously occur in sites not usually targeted by
immunization protocols, such as the CNS. Moreover,
different populations of APCs seem to present soluble
or particulate antigens to CD4 or CD8 T cells (Pooley
et al., 2001; den Haan et al., 2000). Tumor antigen pre-
sentation to CD8 T cells probably occurs most effi-
ciently after crosspresentation by specialized profes-
sional APCs that have been identified for s.c. sites
(Chiodoni et al., 1999) but remain uncharacterized for
the brain (Calzascia et al., 2003).
Our results in H-2KbDb-deficient animals and in radia-
tion chimeras reconstituted with H-2d BM revealed that
proliferation of P14 CD8 T cells following MC57-GP tu-
mor implantation was absent when host APCs are un-
able to present the GP33–41 epitope (Figure 2). This indi-
cates that priming of H-2Db/GP33–41-restricted P14 CD8
T cells is performed by APCs crosspresenting tumor-
derived antigens, and this suggests that hypotheses
proposing inefficient crosspresentation of epitopes
within signal sequence peptides (such as GP33–41)
(Wolkers et al., 2004) may need to be refined. Indeed,
another report has also noted that crosspresentation
was necessary for priming of P14 CD8 T cells in mice
developing spontaneous GP-expressing tumors (Ngu-
yen et al., 2002). In contrast, authors of a previous
study using MC57-GP tumors suggested that direct
presentation of antigens by tumor cells is the main
mechanism of T cell priming in this model (Ochsenbein
et al., 2001). However, direct evidence for the lack of
crosspresentation was only provided for the subdomi-
nant H-2Kd-restricted GP283–291 epitope. In view of the
complexity and polyspecificity of GP-specific CTL im-
mune responses, the relative participation of cross-
priming versus direct priming is facilitated by analyzing
T cells specific for a single epitope such as in the P14
TCR transgenic mice used in the present study. More-
over, considering the central role of T cell/APC interac-
tions in dictating selective homing phenotypes (Stagg
et al., 2002; Mora et al., 2003; Johansson-Lindbom et
al., 2003), the multiple imprinting programs we ob-
served in LNs (Figures 5 and 6) offer further support for
the notion of crosspriming rather than direct priming by
tumor cells, as the latter would be expected to gener-
ate cells with a homogenous phenotype in all sites.
Overall, our data are best interpreted by a mechanism
of phenotypic imprinting in most LNs that is not dic-
tated by specialized APC subtypes constitutively pre-
sent and unique to the LN but rather by incoming cross-
presenting APCs transporting antigens captured in the
upstream tissues. However, it is still unclear whether
the strong bias toward induction of gut-tropic T cells in
gut-associated lymphoid tissue (Peyer’s patches and
mLNs) (Stagg et al., 2002; Mora et al., 2003; Johansson-
Lindbom et al., 2003) is indicative of a unique property
of DCs residing in those lymphoid organs or whether it
is related to the continuous immigration of APCs from
the intestinal lamina propria and other mucosal sites,
necessary for maintaining tolerance to dietary proteins
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wand commensal bacteria and protection against intesti-
anal pathogens (Mowat, 2003). In other lymphoid organs,
LN entry of specialized APCs will mainly occur once an
Tinflammatory response is underway in a given tissue.
T
However, even under these conditions, the LN is not b
polarized to provide a microenvironment for priming T S
fcells with a single tissue-tropism because we showed
tsimultaneous priming of GP-specific or OVA-specific
tCD8 T cells in the same iLN, each expressing distinct
Thoming receptors (Figure 6). Thus, at least in primary
H
immune responses, there is functional compartmental- a
ization within the T cell zones of LNs that may be suffi- 1
scient to ensure efficient regional protection in the
wcontext of multiple antigenic challenges in different
tsites. Our results are consistent with a model of pheno-
typic imprinting mediated by APCs programmed at the C
antigen capture site that subsequently migrate to LNs P
and prime and imprint naive T cells with either cell- s
pmediated interactions, or with tightly controlled secre-
Rtion of soluble factors (Figure 7). An alternative possi-
(bility is that T cells primed and imprinted with a given
7homing phenotype in one LN leave the LN after a few
w
divisions and recirculate to another lymphoid site, E
where there is the potential for further division. This i
ppossibility, although an improbable occurrence under
physiological conditions, cannot be totally excluded in
lthe case of i.p. tumor implantation in our system, in
kwhich P14 CD8 T cells divide in most lymphoid tissues.
l
However, in the case of the 2 homing phenotypes we r
describe in the cLN after i.c. or s.c./neck tumor implan- z
ntations (Figure 5B), such hypothetical T cell recircula-
ation is unlikely to play a major role because the cLNs
are the only significant priming sites for tumors im-
Fplanted by the s.c./neck route (Figure S2).
A
Differential expression of integrins by pathogenic T b
cells has already provided therapeutic targets for block- a
Ming tissue-tropism in autoimmune diseases (von Andriana
i
t
2
h
b
m
h
b
t
E
M
P
T
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Figure 7. Redundancy of LN Identity in Determining CD8 T Cell (
Homing Phenotype m
Schematic representation of pathways that may lead to multiple
Ahoming phenotypes in the same LN, illustrated here for tumors im-
Nplanted i.p. that result in imprinting of a “gut-tropic” phenotype on
fT cells dividing in all LN tested. The concept was also demon-
astrated to be applicable for a “skin-tropic” phenotype that can be
cinduced in cLN when s.c. tumor implantation is in proximity to the
wcLNs (see text and Figure 6).
and Engelhardt, 2003). Furthermore, antitumor T cells
nduced by DC vaccines can be highly regional in pro-
ection against tumors in different sites (Mullins et al.,
003). A better understanding of the factors regulating
oming and adhesion properties of such potentially
eneficial T cell subsets will clearly be required to opti-
ize future immunotherapeutic strategies aimed at en-
ancing homing of protective CTL populations to the
rain (e.g., against tumors and parasitic infections) or
o other peripheral tissues.
xperimental Procedures
ice
14 TCR transgenic mice (Pircher et al., 1989) bearing a Vα2Vβ8.1
CR specific for the H-2Db/GP33–41 complex were provided by H.
ircher (University of Freiburg, Freiburg, Germany). H-2KbDb KO
nimals (Perarnau et al., 1999) were provided by F.A. Lemonnier
Institut Pasteur, Paris, France). C57BL/6, DBA/2, B6D2 and OT-I
ice were from Charles River Laboratories (L’Arbresle, France).
doptive Transfer of P14 or OT-I TCR Transgenic Cells
aive CD8 T cells from P14 or OT-I transgenic mice were purified
rom spleens and LNs using anti-CD8α-coated magnetic bead sep-
ration (Miltenyi Biotech, Bergisch Gladbach, Germany). Fluores-
ent labeling of cells with CFSE (Molecular Probes, Eugene, OR)
as performed as previously described (Nguyen et al., 2002). For
doptive transfer experiments, mice were infused i.v. with 3–5 ×
06 unlabeled or CFSE-labeled cells as indicated. Recipient mice
ere implanted with tumor cells at the indicated sites 2–3 days
fter adoptive transfer.
umor Cell Implantations
he MC57-GP fibrosarcoma (Ochsenbein et al., 2001) was provided
y R.M. Zinkernagel (Institute of Experimental Immunology, Zurich,
witzerland). The E.G7-OVA cell line (CRL-2113, an OVA trans-
ected derivative of EL4) was obtained from the American Type Cul-
ure Collection (Manassas, VA). For s.c. implantations, 3–5 × 106
umor cells in methylcellulose were injected at the indicated site.
he i.p. injections were performed with 3–5 × 106 tumor cells in
BSS. Implantations in the brain were performed with a stereotaxic
pparatus as previously described (Walker et al., 2000), using 5 ×
05 cells in 5 l of methylcellulose injected at 1 l/min with equally
low withdrawal of the needle after injection. All animal procedures
ere approved by the Institutional Ethical Committee and the Can-
onal Veterinary Office.
ell Preparations
eripheral blood mononuclear cells (PBMCs) were purified by Ficoll
eparations. For the isolation of BILs, mice were killed by CO2 as-
hyxia and perfused through the left cardiac ventricle with isotonic
inger’s solution. Brains were enzymatically digested as described
Walker et al., 2000) and cells from each brain were resuspended in
0% Percoll (Amersham Biosciences, Upsalla, Sweden), overlayed
ith 37% and 30% Percoll, then centrifuged for 20 min at 500 × g.
nriched BIL populations were recovered at the 70%–37% Percoll
nterface. For the isolation of hepatic mononuclear cells, livers from
erfused mice were freed of the gall bladder, passed through a 70
m sieve, washed, then resuspended in 40% Percoll, and over-
ayed onto 80% Percoll. After centrifugation (10 min, 800 × g), leu-
ocytes were harvested from the 80%–40% Percoll interface. For
ung-infiltrating lymphocytes, lungs from perfused mice were
oughly chopped, digested for 30 min at 37°C using the same en-
yme mix as for brain, dissociated by forcing through syringes with
eedles of decreasing bore diameter, further digested for 20 min,
nd finally filtered through a 70 m sieve.
low Cytometry
fter blocking Fc receptor binding, the following monoclonal anti-
odies were used (BD Pharmingen, San Diego, CA): CD8 (53-6.7):
nti-α4β7 integrin (DATK32), CD62L (MEL-14), CD103 (αEβ7 integrin,
290), anti-β integrin (HMβ1-1) anti-β integrin (M293) and anti-1 7
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183Vα2 (B20.1). The anti-β7 integrin antibody (M293) detects all pos-
sible β7 heterodimers (i.e., α4β7 and αEβ7). CD49d (α4 integrin, PS/2)
and CD11b (αM integrin, M1/70) antibodies were purified in house
(M.A.-L.). Vβ5 specific antibody was kindly supplied by S. Izui (Ge-
neva University, Switzerland). Selectin ligand expression was ana-
lyzed using recombinant murine E-selectin-human Fc fusion pro-
tein (R&D Systems, Abington, UK) and P-selectin-human Fc fusion
protein (BD Pharmingen), with human CD40L-human Fc fusion pro-
tein as negative control (kindly provided by B. Huard, Geneva Uni-
versity, Switzerland). Secondary antibodies used were PE-conju-
gated goat anti-rat IgG (Southern Biotech, Birmingham, AL) or goat
anti-hamster IgG (Immunokontact, Lugano, Switzerland) for reveal-
ing integrin specific staining and PE-conjugated goat anti-human
IgG for revealing selectin specific binding (Jackson ImmunoRe-
search Laboratories, West Grove, PA). Streptavidin-CyChrome (BD
Pharmingen) was used for revealing staining with biotinylated pri-
mary antibodies. All flow cytometric analysis was performed on
live-gated cells using a FACScan (Becton Dickinson, Palo Alto, CA).
In Vitro Restimulations
In vitro restimulations were performed by coculturing cLN-derived
cells from H-2KbDb KO animals with C57BL/6 irradiated spleno-
cytes pulsed with the GP33–41 epitope (KAVYNFATM) or an irrele-
vant H-2Kb binding peptide (OVA257–264, SIINFEKL). DMEM medium
supplemented with 20 M βME and 30 U/ml recombinant human
IL-2 (Chiron Corporation, Emeryville, CA) was used for the entire
culture period. Division of CFSE-labeled cells was assessed by
flow cytometry after 3 days of culture.
Generation of Bone Marrow Chimeras
Recipient B6D2 mice were irradiated with two doses of 500 cGy 6
hr apart. After an additional 16 hr, mice were injected i.v. with 107
BM cells (B6D2 or DBA/2). Chimeras were allowed to reconstitute
for at least 7 weeks before use. Reconstitution of blood lymphocyte
populations was confirmed by FACS analysis with H-2-specific an-
tibodies.
In Vivo Homing Assay
Cells were isolated from cLNs and iLNs 4 days after i.c. or s.c.
MC57-GP implantation into C57BL/6 mice that had been previously
infused with 3–5 × 106 unlabeled naive P14 CD8 T cells. Culture
was in 6-well plates at a concentration of 5 × 106 cells/4 ml of
DMEM medium containing 6% FCS, supplemented with 20 M
βME and 30 U/ml recombinant human IL-2 (Chiron Corporation).
After 72 hr, cells were harvested, purified by magnetic bead separa-
tion to obtain CD8+ fractions, then labeled with two different con-
centrations of CFSE: 10 M for cLN and 1 M for iLN. Cells were
then mixed at a 1:1 ratio and 4–6 × 106 cells infused i.v. into C57BL/
6 mice implanted i.c. 6 days previously with 2x105 MC57-GP tumor
cells. For inhibition experiments, 150 g/mouse of a control anti-
body (CD11b, clone M1/70) or a CD49d antibody (α4 integrin, clone
PS/2) was added to the cell mix before i.v. infusion. Antibodies
were purified from serum-free culture supernatants by ammonium
sulfate precipitation. 24 hr later, the relative ratio of CFSEhigh (cLN
cells) versus CFSElow (iLN cells) in activated (i.e CD62L−) CD8 T
cells was assessed by flow cytometry of leukocytes isolated from
blood, brain, lung, liver, and spleen. The migration index represents
the ratio between the proportion of CFSEhigh and CFSElow cells in
the CD8+CD62L− fraction of each cell populations (corrected for
the ratio in the input population).
Supplemental Data
Supplemental Data including three additional figures are available
at http://www.immunity.com/cgi/content/full/22/2/175/DC1/.
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